Systemic therapy in metastatic pancreatic adenocarcinoma: current practice and perspectives

Major breakthroughs have been achieved in the management of metastatic pancreatic ductal adenocarcinoma (PDAC) with FOLFIRINOX (5-fluorouracil + irinotecan + oxaliplatin) and gemcitabine plus nab-paclitaxel approved as a first-line therapy, although the prognosis is still poor. At progression, patie...

Descripción completa

Detalles Bibliográficos
Autores principales: Lellouche, Lisa, Palmieri, Lola-Jade, Dermine, Solène, Brezault, Catherine, Chaussade, Stanislas, Coriat, Romain
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Advances in Treatment of Lung Cancer Patients with Targetable Mutations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8264726/
https://www.ncbi.nlm.nih.gov/pubmed/34285720
http://dx.doi.org/10.1177/17588359211018539

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8264726/
https://www.ncbi.nlm.nih.gov/pubmed/34285720
http://dx.doi.org/10.1177/17588359211018539

Ejemplares similares